Monsignore Lucas Moretti, Elias-Junior Jorge, Muglia Valdair Francisco, Teixeira Andreza Correa, Mente Enio David, Martinelli Ana de Lourdes Candolo, Abud Daniel Giansante
Divisão de Radiologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
Divisão de Cirurgia Digestiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
Clinics (Sao Paulo). 2015 Dec;70(12):781-9. doi: 10.6061/clinics/2015(12)04.
Transarterial chemoembolization is the treatment of choice for intermediate-stage hepatocellular carcinoma. However, there are no clear data supporting transarterial chemoembolization vs . transarterial embolization or regarding the best chemotherapeutic agent, which may suggest a preponderant role of ischemia over chemotherapeutic action. This study sought to evaluate the radiological response and outcome of transarterial chemoembolization modified by n-butyl cyanoacrylate addition compared to conventional transarterial chemoembolization in hepatocellular carcinoma patients.
A retrospective review identified forty-seven patients who underwent modified chemoembolization and thirty-three who underwent conventional chemoembolization between June 2006 and December 2011. The radiological response was reassessed using the modified Response Evaluation Criteria in Solid Tumors. The sustained complete response, time to progression and overall survival rates were also analyzed.
Complete response rates were significantly higher in patients who had undergone modified chemoembolization compared to those who had undergone conventional treatment (61.7% and 24.3%, respectively; p < 0.001). The rate of sustained complete response was significantly higher in the modified chemoembolization group compared to the conventional chemoembolization group (median of 236 and 37 days, respectively; p < 0.001). Time to progression was significantly higher in the modified chemoembolization group compared to the conventional chemoembolization group (median of 424 and 201 days, respectively; p = 0.042). Overall survival rates revealed no difference between patients who received modified chemoembolization and conventional chemoembolization (median of 483 and 399 days, respectively; p = 0.316).
Transarterial chemoembolization modified by n-butyl cyanoacrylate addition was superior to conventional transarterial chemoembolization in terms of the radiological response in the first imaging control. Although the sustained complete response and time to progression rates were higher for the modified chemoembolization group, no differences in overall survival rates were observed.
经动脉化疗栓塞术是中期肝细胞癌的首选治疗方法。然而,目前尚无明确数据支持经动脉化疗栓塞术与经动脉栓塞术的对比,也没有关于最佳化疗药物的数据,这可能表明缺血比化疗作用占主导地位。本研究旨在评估在肝细胞癌患者中,与传统经动脉化疗栓塞术相比,添加氰基丙烯酸正丁酯改良后的经动脉化疗栓塞术的放射学反应和疗效。
一项回顾性研究确定了2006年6月至2011年12月期间接受改良化疗栓塞术的47例患者和接受传统化疗栓塞术的33例患者。使用改良的实体瘤疗效评价标准重新评估放射学反应。还分析了持续完全缓解率、疾病进展时间和总生存率。
与接受传统治疗的患者相比,接受改良化疗栓塞术的患者完全缓解率显著更高(分别为61.7%和24.3%;p<0.001)。改良化疗栓塞术组的持续完全缓解率显著高于传统化疗栓塞术组(中位数分别为236天和37天;p<0.001)。改良化疗栓塞术组的疾病进展时间显著高于传统化疗栓塞术组(中位数分别为424天和201天;p = 0.042)。接受改良化疗栓塞术和传统化疗栓塞术的患者总生存率无差异(中位数分别为483天和399天;p = 0.316)。
在首次影像学检查中,添加氰基丙烯酸正丁酯改良后的经动脉化疗栓塞术在放射学反应方面优于传统经动脉化疗栓塞术。虽然改良化疗栓塞术组的持续完全缓解率和疾病进展时间率更高,但总生存率未观察到差异。